IDCC

InterDigital, Inc.

Technology · USD

Set alert

Price alert · IDCC

All alert types
311.57 USD -22.70 -6.79%
As of Oct 30, 2026 Extended hours 311.57 0.00%
Bid
311.56 × 2
Ask
311.99 × 1
306.25 Day range 327.43
250.75 52-week range 396.54
YTD
-2.14%
1 year
-21.39%
Open
327.43
Prev close
334.27
Mkt cap
8.02B
Vol
266.94K
Avg vol
199.23K
EPS
8.56
P/E
36.40
Div yield
0.90%
More statistics
Low
306.25
High
327.43
Forward P/E
27.66
Beta
0.00
Short ratio
14.00
Inst. own
109.18%
Dividend
3.00
Ex-div date
Oct 13, 2026
Earnings
Feb 4, 2027
50-d avg
332.31
200-d avg
317.90
1y target
462.67

5D chart

Chart tools
Interval
IDCC five-day price chart317.1326.0334.8343.7352.5Oct 26Oct 27Oct 28Oct 29

Discussion (2)

Sign in to join the discussion

Gemma wood IDCC 2 years ago #1

I have been trading for more than 6 years and Alfred Thomson trading strategy is a system that I always tell people to use, the right strategy when they are trading. His strategy is consistent and accurate which makes it one of the best systems out there. Get to him on telegram @Alfredsignals1

VICKY HANUKA IDCC 3 years ago #2

$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.